- START HERE Start Your 7-Day Evaluation
Located primarily in the brain and central nervous system, CB1 receptors help regulate the release of neurotransmitters that amplify pain signals.
CB2 receptors are found throughout the immune system and peripheral tissues, where
they help regulate inflammatory responses.
Researchers such as Dr. Raphael Mechoulam, who first discovered THC, and Dr. Ethan
Russo, who introduced the concept of Clinical Endocannabinoid Deficiency, have
emphasized the important role the ECS plays in pain regulation.
For new users beginning the 7-Day Evaluation, we recommend:
1 capsule twice daily
Increase to 2 capsules twice daily if additional support is desired.
Our formulations have been refined through over eight years of research, formulation development, and real-world field testing.
Because each individual responds differently to Endocannabinoid System (ECS)
supplements, we created the ECS Therapy 7-Day Evaluation Program.
This program allows individuals to explore how ECS modulation may support their body’s natural balance.
Start with 1 capsule twice daily
Increase to 2 capsules twice daily if additional support is desired.
The Godfather of Cannabis Research Isolated and synthesized THC and CBD, fundamentally reshaping our understanding of cannabinoids and discovering the endocannabinoid system itself. Without Dr. Mechoulam’s foundational work, none of this would exist. When he responded to my email in May 2019 with his clinical trial data, he gave me the blueprint for what ECS modulation could be.
Demonstrated that terpenes and cannabinoids work synergistically, proving that “the sum of all the parts” is greater than isolated components. His 2016 paper “Beyond Cannabis: plants and the endocannabinoid system” expanded the conversation beyond a single plant—showing that the ECS is larger than cannabis alone. His research directly supports what we’re doing.
The Advocate for Real-World Science Conducted the first FDA-approved randomized controlled trial assessing the safety and efficacy of cannabis in military veterans with PTSD, fighting federal barriers to conduct rigorous clinical research on whole-plant medicine. Dr. Sisley’s persistence—filing lawsuits against the DEA, breaking the federal monopoly on cannabis research—proved that real-world cannabinoid research matters more than pharmaceutical shortcuts.
Pioneer of Raw Cannabinoid Research First to systematically study THCA, CBDA, and other raw cannabinoid precursors, demonstrating that cannabinoids in their natural (non-heated) form have therapeutic potential superior to decarboxylated forms at lower doses. His work expanded my understanding of the complete cannabinoid spectrum and why Phase 2 formulations will use raw cannabinoid compounds alongside decarboxylated forms.
Co-Discoverer of the Entourage Effect Collaborated with Dr. Mechoulam in 1998 to propose the concept that compounds work better together than in isolation. This foundational principle—botanical synergy—is the entire philosophy behind ECS Therapy’s three-layer approach.
Pioneer of Clinical Cannabinoid Medicine & Patient-Centered Education Founded Integr8 Health (serving 8,000+ patients with medical cannabis) and Healer.com, providing rigorous education on the endocannabinoid system and clinical cannabinoid protocols. His work bridges the gap between scientific research and real-world patient application. I studied his comprehensive courses on ECS science, cannabinoid dosing, and condition-specific treatment guidelines—education that became foundational to how I approach formulation and patient outcomes. Dr. Sulak’s emphasis on “using the correct dose” and understanding the ECS at every level directly informed ECS Therapy’s precision approach.
These statements have not been evaluated by the Food
and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease. Consult your physician before use if you are
pregnant, nursing, or taking any medication.
© 2026 ECS Therapy. All Copyright Reserved – Design By Bmybrand